Nivolumab plus ipilimumab (N+I) in patients (pts) with solid tumors with high tumor mutational burden (HTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Journal of Clinical Oncology

Topics

Computer Science

Cancer Oncology

Medicine

Internal Medicine

Nivolumab

Show all topics

DOI

10.1200/jco.2024.42.16_suppl.3130